Hexoline

Quick links to important sections

Hexoline

Method of action: Bronchodilator, Tocolytic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hexoline

Hexoline is a pharmaceutical preparation defined by its active ingredient, Hexoprenaline, a synthetic compound belonging to the class of sympathomimetic agents. It is clinically recognized for its high specificity, which targets particular smooth muscle tissues.


Quick Facts

Property Description
Active ingredient Hexoprenaline (Hexoprenaline sulfate)
Form Tablets, Syrup, Solution for injection
Pharmacological class Selective beta2-Adrenergic Receptor Agonist
Common Use Smooth muscle relaxation (e.g., airways, uterus)
Origin Synthetic compound

Identity, Class, and Composition

The entity at the core of Hexoline is the international nonproprietary name (INN) Hexoprenaline, typically prepared as Hexoprenaline sulfate. This allopathic medicine is a phenethylamine derivative that functions as a highly selective Beta-2 Adrenergic Receptor Agonist. This selective classification is a key differentiating factor, indicating a focused pharmacological approach compared to older, less specific agents in the sympathomimetic group. Within the ATC classification system, Hexoprenaline is listed under code R03CC05 for systemic use. It is a single-ingredient product, meaning its effect relies solely on the actions of Hexoprenaline.

General Purpose and Available Forms

The general purpose of Hexoline is to induce smooth muscle relaxation to effectively manage unwanted constriction or spasm. This therapeutic capability grants the medicine a dual classification as both a bronchodilator agent and a tocolytic agent. This functional duality means the medicine helps manage conditions where targeted muscle relaxation in the airways or the uterus is necessary. Hexoline is manufactured in several distinct dosage forms, which include both tablets and a liquid syrup for oral intake, as well as a sterile solution for injection suitable for intravenous administration when an immediate effect is required.

What side effects are possible with Hexoline?

Possible Side Effects and Safety Information

The safety profile of Hexoline (Hexoprenaline), a selective sympathomimetic agent, is primarily characterized by cardiovascular and neurological effects consistent with its pharmacological class. Official regulatory documentation classifies these effects according to frequency and body system involved.


Adverse Reaction Classification

Adverse reactions are organized by the System-Organ-Class (SOC) they affect, with the most frequently observed effects linked to the drug's action on the heart and nervous system. Cardiovascular disorders include maternal tachycardia (very common with intravenous use), palpitations, and maternal hypotension (common). Effects on the nervous system often include tremor and headache.

Classification Tier Representative Adverse Reactions
Very Common Maternal Tachycardia (rapid maternal heart rate)
Common Palpitations, Maternal Hypotension, Tremor, Headache

Serious Safety Considerations and Constraints

Regulatory sources document the potential for serious adverse reactions, particularly with intravenous administration for obstetric indications. These rare, clinically significant effects include pulmonary oedema (fluid in the lungs) and cardiac arrhythmias (irregular heart rhythm).

Due to the cardiovascular risk profile, the medicine is subject to safety constraints. It is contraindicated in individuals with pre-existing heart conditions, such as Ischemic Heart Disease and certain Cardiac Arrhythmias, as well as Uncontrolled Hypertension and Hyperthyroidism. Furthermore, common adverse reactions, such as tachycardia and tremor, are strongly linked to the intravenous route of administration and may be observed during exposure.

Overdose and Emergency Response

The official regulatory documents define the Hexoprenaline overdose profile based on the consequences of excessive β-adrenergic stimulation, which necessitates immediate medical intervention.

Documented Overdose Manifestations

Overdose presentations are primarily characterized by excessive sympathetic effects. Documented signs include tachycardia (rapid heart rate), palpitations, and skeletal muscle tremor. Other manifestations that may occur are headache, nervousness, anxiety, restlessness, and dizziness.

Severe Outcomes and Required Action

Over-exposure carries the risk of severe and life-threatening complications affecting the cardiovascular and metabolic systems. These outcomes include serious arrhythmias, potentially leading to ventricular dysrhythmias, and episodes of severe hypertension. Metabolic disturbances such as hyperglycemia and hypokalemia are also documented. Regulators mandate that immediate medical attention is required for any indication of a severe reaction or suspected overdose.

Management and Monitoring Requirements

The management of overdose is symptomatic and supportive. Due to the cardiovascular risk, close monitoring of vital signs, including heart rate and blood pressure, is required. Furthermore, monitoring of metabolic parameters, specifically blood glucose and serum potassium levels, is necessary to address documented disturbances. In patients with pre-existing heart conditions, the severity of cardiovascular outcomes is officially cautioned to be amplified in an overdose scenario.

Therapeutic Uses of Hexoline

What Hexoline Treats: Main Uses and Benefits

Hexoline is commonly used across domains where additional symptomatic support is needed. Hexoprenaline is an agent considered relevant in therapeutic areas requiring bronchodilation and tocolysis.


Symptomatic Relief for Airway Constriction

This domain is applicable within clinical settings that involve acute or unstable symptom patterns, such as flare-ups of conditions characterized by periods of heightened symptoms, including asthma and COPD. Hexoline helps address symptom clusters that may appear suddenly, such as wheezing and shortness of breath. It contributes to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability by easing the overall symptom load.

Supportive Management of Premature Uterine Activity

Hexoline is applied in scenarios where additional management of discomfort is required due to threatened preterm labor. It is commonly used to help with acute episodes of unwanted muscular activity in the uterus. This supportive benefit helps maintain a sense of stability when labor-related symptoms become more noticeable, supporting the patient during a difficult episode.

“Applied across domains where additional symptomatic support is needed, this medicine helps manage symptoms that create noticeable physiological strain.”

Quick Fact: Supportive Management for Spasm-Related Symptoms
Conditions involving acute spasm, such as bronchospasm and threatened preterm labor, are relevant areas of use.
Therapeutic domains are associated with symptomatic relief in areas involving increased muscular tension.

Eligibility and Restrictions for Use

Who can and cannot use Hexoline?

Hexoline (Hexoprenaline) eligibility is strictly defined by regulatory authorities, with contraindications primarily focused on cardiovascular health and specific conditions during pregnancy. The medicine is generally permitted for adults for labeled uses, including the management of bronchospasm. Use in the pediatric population for bronchodilation is permitted in some regions, while use in older adults requires caution due to an increased risk of cardiovascular adverse reactions.

Contraindicated Populations

Official documents state that Hexoline must not be used in individuals with:

  • Documented hypersensitivity to Hexoprenaline or any formulation component.
  • Pre-existing, uncontrolled cardiovascular diseases, including ischaemic heart disease, severe cardiac arrhythmias, myocarditis, aortic stenosis, or uncontrolled hypertension.
  • Severe or uncontrolled hyperthyroidism or angle-closure glaucoma.

Restrictions During Pregnancy and Lactation

Status Regulatory Rule (Obstetric Use)
First Trimester Contraindicated
Tocolysis Restricted to 48 hours maximum, administered only via injection, and only between 22 and 37 weeks of gestation. Oral forms are contraindicated for all obstetric use.
Lactation Not Recommended (Limited safety data)

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Hexoline (Hexoprenaline) is defined by specific pharmacodynamic (PD) interactions, which classify substances that must be avoided or used with documented caution due to antagonism or potentiation of the drug's effects. The regulatory basis focuses on establishing strict PD constraints.

Formal Contraindicated Combinations

Co-administration is explicitly prohibited with several specific agents and classes of medicine due to the documented potential for severe adverse effects through pharmacodynamic reinforcement. These substances are:

  • Monoamine oxidase inhibitors (MAOIs)
  • Tricyclic Antidepressants (TCAs)
  • Ergot Alkaloids
  • Dihydrotachysterol

Pharmacodynamic Interactions and Restrictions

Regulatory documents note several specific PD interactions:

Interaction Type Interacting Agent Official Outcome
Antagonism Non-selective Beta-blockers Documented to reduce or neutralize therapeutic activity.
Additive Risk General Anaesthetics, Adrenergic Agonists Increased documented risk of cardiovascular side effects, such as arrhythmia.
Electrolyte Risk Non-potassium-sparing Diuretics Creates additive PD risk, potentially exacerbating the risk of hypokalemia (low potassium).
Substance Interaction Methylxanthines (e.g., Caffeine) Officially documented to increase the drug's action and potentiate associated systemic risks.

No pharmacokinetic (CYP enzyme) or mandatory timing-based separation rules are explicitly cited in official regulatory text.

Mechanism of Action

Selective Targeting of beta2-Adrenergic Receptors

The pharmacological action of Hexoprenaline is defined by a molecular cascade that produces smooth muscle relaxation, mediated by the peripheral nervous system's regulatory mechanisms. The mechanism begins with Hexoprenaline acting as a selective agonist on the beta2-Adrenergic Receptor (ADRB2), a G-protein coupled receptor present on certain smooth muscle tissues. This interaction initiates the signaling sequence, and the receptor's distribution determines the primary muscle cells where the physiological changes occur.


Intracellular cAMP Signaling and Relaxation Cascade

Upon ADRB2 activation, a coupled Gs protein stimulates the enzyme Adenylate Cyclase, leading to a rapid increase in the second messenger, cyclic AMP (cAMP), inside the cell. The elevated cAMP level activates Protein Kinase A (PKA), which ultimately inhibits the enzyme (MLCK) responsible for triggering muscle contraction and promotes the reduction of free intracellular calcium ions ( Ca^2+). This molecular cascade prevents the smooth muscle cell's capacity to contract, leading to a state of sustained smooth muscle relaxation.


Mechanism Limitations (Desensitization)

The drug's response is constrained by a biological feedback mechanism known as receptor downregulation or tachyphylaxis. Prolonged or frequent exposure to the agonist can lead to the phosphorylation and internalization of the ADRB2 receptors, reducing their number and responsiveness. This physiological process results in a diminished receptor population, which directly restricts the primary biological target available for subsequent binding events.

Dosage and Administration Information

How to Use Hexoline: Official Administration Guidelines

Hexoline, containing the active substance Hexoprenaline, is administered through several officially approved routes, depending on the clinical scenario. These methods include oral intake (tablets or syrup), inhalation (aerosol or nebulisation), and intravenous (IV) injection or infusion.

Administration Routes and Dosing Patterns

Usage Context Official Dosing Regimen Route and Frequency Administration Constraint
Bronchodilation (Oral) 0.5 mg to 1 mg (as sulfate) per dose. Oral, up to three times a day (TID). Swallow tablets whole with liquid.
Bronchodilation (Inhalation) 100 mug to 200 mug per dose. Inhalation, up to six times a day. Max dose for nebulisation: 3 mg/day.
Tocolysis (Acute IV) 10 mug IV loading dose, followed by infusion (e.g., 0.3 mug/minute). Intravenous (IV), continuous infusion. Loading dose must be injected slowly over 5–10 minutes.

Procedural and Time Constraints

The intravenous use of Hexoprenaline, typically initiated in a hospital setting and reserved for specific obstetric needs, is subject to strict time limits. Parenteral administration is generally limited to a maximum of 48 hours. Furthermore, the use of parenteral forms for tocolysis is generally indicated for patients between 22 and 37 weeks of gestation. Oral and suppository forms are not authorised for any obstetric indication due to regulatory restrictions.

Recent Clinical Evidence

Hexoline (Hexoprenaline) has undergone evaluation through clinical studies across two primary therapeutic areas where its muscle-relaxing properties are relevant: supportive management of premature uterine activity and symptomatic relief for airway constriction.

Evidence for Supportive Management of Premature Uterine Activity

Hexoline was studied for conditions characterized by acute episodes, specifically threatened preterm labor in pregnant women. The research base involves Randomized Controlled Trials (RCTs) and Systematic Reviews that examined Hexoprenaline against other agents. Research scenarios explored the measurement of Latency to Delivery, recording the time elapsed before birth occurs, particularly focusing on the measurement of delivery delay up to 48 hours. Studies also monitored outcomes related to Neonatal Status.

Findings describe patterns observed in the studies related to the measurement of this short-term delay. However, certainty remains low for observed patterns related to long-term health outcomes. Reports on outcomes related to Neonatal Status exhibited variability across the research, and limited information is available for long-term infant outcomes.


Evidence for Symptomatic Relief for Airway Constriction

Hexoline was evaluated in research exploring episodic symptom patterns in conditions such as asthma and chronic bronchitis, which involve periods of heightened symptoms. The evidence relies on Randomized Controlled Trials (RCTs) that monitored the medicine’s effect when administered during episodes where symptoms become more noticeable.

Research examined outcomes related to functional imbalance by measuring objective parameters of Lung Function, specifically Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow (PEF). Comparative trials describe patterns observed in the measurement of lung function compared to other agents. Studies also explored the Duration of Action, with findings indicating a measured effect that was observed over a period of hours post-administration. Research describes patterns where the findings were observed to be equivocal in comparisons with some alternative agents, and evidence suggests a potential for a shorter duration of action for some formulations compared to alternatives.

Key Studies & References

  1. Hexoprenaline Compared with Atosiban as Tocolytic Treatment for Preterm Labor (Retrospective cohort study informing on comparative short-term measurements and variability of neonatal outcomes)

Frequently Asked Questions (FAQ)

Common questions about Hexoline (FAQ)

Q: Does Hexoline have any common side effects?

Official regulatory documents describe a profile of frequently observed side effects, which is consistent with the drug’s pharmacological class. These common effects include neurological symptoms like headaches and tremors, as well as cardiovascular effects like palpitations and feelings of nervousness. A complete list of all known adverse effects is detailed in the safety information section of the product labeling.

Q: Is Hexoline safe to use for people with kidney issues?

Regulatory documents indicate that the use of Hexoline requires caution or may be not recommended in individuals who have pre-existing kidney diseases or severe renal impairment. This guidance is based on how the body processes medications in the presence of existing conditions. The suitability for use is addressed by a healthcare professional, especially when other pre-existing conditions are present.

Q: What kind of research has been done on Hexoline?

Research supporting the medicine's use has focused on two primary applications: its role as a bronchodilator and as a tocolytic agent (to manage premature uterine activity). Studies often use Randomized Controlled Trials and Systematic Reviews to measure outcomes. For instance, research examines lung function improvements and the delay to delivery in obstetric settings.

Q: Do regulatory agencies list any rare side effects for Hexoline?

Yes, official safety documents categorize certain effects as less common but serious adverse reactions, particularly when the medicine is administered intravenously. These include conditions such as fluid in the lungs (pulmonary oedema) and irregularities in heart rhythm (cardiac arrhythmias). These serious risks are explicitly detailed in regulatory safety constraints.

Q: How does Hexoline fit into the standard treatment guidelines?

The medicine is officially used to induce smooth muscle relaxation, allowing it to function as a bronchodilator or a tocolytic agent. In the specific context of tocolysis (managing premature uterine activity), beta2-agonists like Hexoline are categorized as a preferred option in some European clinical guidelines and treatment protocols.

Q: How quickly does Hexoline start working?

The onset of effect depends on the route of administration. When Hexoline is given by inhalation, the official product information indicates that the active ingredient is rapidly absorbed through the respiratory passages. If administered intravenously (by injection), the effect is described as achieved rapidly in the systemic circulation.

Q: How long does the effect of Hexoline last?

Official data describes the pharmacological duration in terms of its elimination half-life, which is the time it takes for half the drug to be cleared from the system. For Hexoline, this half-life typically ranges from one to three hours.

Q: Why do some people stop taking Hexoline?

Like many medications, some individuals may discontinue use due to the occurrence of unwanted side effects. Clinical data indicates that common cardiovascular effects, such as palpitations (feeling a rapid heart rate), can be a reason for switching to a different therapy.

Q: What is the main chemical component of Hexoline?

The active ingredient in Hexoline is Hexoprenaline, which is a synthetic compound typically prepared as a sulfate salt. Chemically, it is classified as a phenethylamine derivative and has the molecular formula C22 H32 N2 O6.

Q: Can Hexoline affect sleep patterns?

Official regulatory safety documents list nervousness as one of the commonly observed side effects of Hexoline.

Q: Can Hexoline be crushed or broken if swallowing is difficult?

The official administration guidance for the oral tablet formulation is explicit, stating that the medicine must be swallowed whole with liquid. As a general principle of administration, tablets are not to be modified unless an explicit regulatory instruction permits crushing or breaking.

Q: What are the most commonly reported reasons for discontinuation of Hexoline in trials?

In clinical studies, the most reported reasons for discontinuing or switching away from Hexoline often related to the frequency of specific adverse effects. These commonly observed effects included maternal tachycardia (a rapid heart rate) and palpitations.

Q: What should a patient do if they suspect an interaction with Hexoline?

Official patient information indicates that individuals should contact a healthcare provider if they suspect a drug interaction or experience unexpected effects. These experts can provide non-directive, appropriate guidance based on the individual’s circumstances.

Q: Is Hexoline a medication that needs to be taken long-term?

The required duration for taking Hexoline depends on the condition it is treating. While intravenous use is regulatory limited to a maximum of 48 hours for specific obstetric needs, the duration of use for oral or inhalation forms is addressed by the prescribing healthcare professional based on the individual's condition.

How should Hexoline be stored and disposed of?

How to Store and Dispose of Hexoline

The storage and disposal of Hexoline (Hexoprenaline sulfate) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Hexoline must be stored at Controlled Room Temperature (CRT), typically defined as 20 C to 25 C. It is mandatory to protect the product from light and excessive humidity by keeping it in its original container and ensuring the container is tightly closed.

Regulatory documents explicitly state that the medicine must not be frozen.

As a requirement for all prescription medicines, Hexoline must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Hexoline should prioritize using a drug take-back program or an authorized collector. If a take-back program is unavailable, the medicine must be prepared for household trash by mixing it with an unappealing substance (such as coffee grounds) and securing it in a sealed bag. The medicine should not be flushed down a toilet or poured into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hexoline found in:

A-Z Index: